Companies › Accutar Biotechnology
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AC676 | – | Phase 1 | Relapsed/Refractory B-cell Malignancies | – |
| AC699 | – | Phase 1 | Breast Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05654532 | AC699 | Phase 1 | Breast Cancer | Oncology | Mar 2026 |
| NCT05780034 | AC676 | Phase 1 | Relapsed/Refractory B-cell Malignancies | Oncology | Mar 2026 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.